Marrone Bio announced results for 2019 field trials for MBI-015 bioherbicide
Marrone Bio Innovations announced positive results for the 2019 field trials for its novel bioherbicide, known as MBI-015. Field tests conducted in 2019 using commercial rates for Marrone Bio's novel bioherbicide demonstrated control of a target weed approaching that of a current post-emergent chemical herbicide. At commercial rates across multiple trial locations that used uniform protocols, control of palmer amaranth was evaluated at three stages of growth, 7-to-10 days after MBI-015 was applied. Control ranged from the mid-70s to the high-80s percent ranges. The company also has been issued U.S. Patent 8,822,193, which covers claims related to pre- and post-emergent herbicidal activity to control weeds for its bioherbicide. Additional regulatory and patent submissions are planned for both MBI-015, a liquid formulation for use in conventional crops, and MBI-014, a granular formulation of the bioherbicide targeted for organic use. The company also holds patents related to the underlying bacteria used in the bioherbicide and its associated pesticidal compounds.